The anti-angiogenic activity of (+)-catechin as well as its regulatory effect on the production of nitric oxide and TNFα were studied using in vivo and in vitro models. In vivo angiogenic activity was studied using B16F-10 melanoma cell-induced capillary formation in C57BL/6 mice. Administration of (+)-catechin significantly inhibited (36.09%) the number of tumour-directed capillaries induced by injecting B16F-10 melanoma cells on the ventral side of C57BL/6 mice. The cytokine profile in the serum of these animals showed a drastically increased level of proinflammatory cytokines such as IL-1β, IL-6, TNF-α, GM-CSF and the direct endothelial cell proliferating agent, VEGF. Administration of (+)-catechin could differentially regulate elevation of these cytokines. The differential elevation is further evidenced by the increased production of IL-2 and tissue inhibitor of metalloproteinase-1 (TIMP-1) in the B16F-10 injected, (+)-catechin-treated animals. In vitro L929 bioassay revealed the inhibition of TNF-α production by (+)-catechin treatment. In the rat aortic ring assay, (+)-catechin inhibited the microvessel outgrowth at non-toxic concentrations. (+)-Catechin at non-toxic concentrations (5-25 µg/ml) showed significant inhibition in the proliferation, migration and tube formation of endothelial cells, which are the key events in the process of angiogenesis. (+)-Catechin also showed inhibitory effect on VEGF mRNA levels in B16F-10 melanoma cells. (+)-Catechin inhibited the production of NO and TNF-α in LPS-stimulated primary macrophages. Taken together, these results demonstrate that (+)-catechin inhibits tumour-specific angiogenesis by regulating the production of pro-and anti-angiogenic factors such as pro-inflammatory cytokines, nitric oxide, VEGF, IL-2 and TIMP-1. These results also suggest that (+)-catechin could significantly inhibit nitrite and TNF-α production in LPS-stimulated macrophages.
INTRODUCTION
Vasculogenesis is a process whereby angioblasts differentiate into endothelial cells (ECs) and, in turn, ECs proliferate to form a de novo primitive vascular network in an avascular tissue. 1 The primitive vascular network is modified via angiogenesis, which leads to maturation, branching and formation of a complex vasculature that is seen in adult life. Angiogenesis involves pruning, intussusception and enlargement of vessels, concomitant with an increased interaction of ECs with the surrounding extracellular matrix (ECM), pericytes (PCs) and smooth muscle cells (SMCs), creating a stabilized vascular network. [1] [2] [3] Angiogenesis is also the process that takes place during adult life when new vessel formation is required, such as in physiological conditions of wound healing and pregnancy or in pathological conditions such as tumour angiogenesis, ischaemia, vascular malformations and inflammatory reactions. In pathological angiogenesis, the autocrine, paracrine and amphicrine interactions of the vascular endothelium with the proangiogenic and angiostatic cytokines and growth factors are irregularly regulated, which was tightly regulated both spatially and temporally in physiological angiogenesis. 4 Among the known angiogenic growth factors and cytokines implicated in the modulation of angiogenesis, vascular endothelial growth factor (VEGF), nitric oxide (NO) and pro-inflammatory cytokines play paramount and indispensable roles in regulating the multiple facets of the angiogenic and lymphangiogenic process. [4] [5] [6] The role of VEGF on human melanoma metastasis to the lymph node is well established. 7 As a central mediator of angiogenesis, VEGF has emerged as an important target for angiogenic therapy.
The earliest stages of angiogenesis are defined by vasodilation mediated by nitric oxide (NO) and an increased vascular permeability of pre-existing capillaries or post-capillary venules in response to VEGF. 8 Nitric oxide is a multifunctional species that is implicated in a wide variety of physiological and pathological processes. 9, 10 It is an essential physiological signalling molecule mediating various cell functions but also induces cytotoxic and mutagenic effects when present in excess, thus pointing its dual role in biological system. 10 NO 2 - and NO 3 - in plasma reflect the level of NO formation. 11 A family of three isoenzymes called nitric oxide synthase produces NO from L-arginine, 10, 12 of which two are constitutively expressed (cNOS) and a third is inducible by immunological stimuli (iNOS). Vasodilation by smooth muscle relaxation, mediated by NO, is a prerequisite for the endothelial cell to enter the angiogenic cascade 8 and increased NO production correlates positively with increase of vascular density and tumour growth. 13 The pro-inflammatory cytokine, TNF-α, has been demonstrated to be a mediator of NO synthesis. 14 Activated macrophages and monocytes produce TNF-α which, in turn, induces various immune responses, such as the release of soluble mediators like PGE 2 , leukotrienes, platelet activating factor, NO and reactive oxygen intermediates. 15 Lipopolysaccharide (LPS), an endotoxin obtained from Gram-negative bacteria, has been shown to be a potent inducer of TNF-α. 15 Inflammation is a response of vascularized tissue to sublethal injury 16 and considered as one of the major contributors of carcinogenesis. The pro-inflammatory cytokines such as IL-1β, IL-6, TNF-α and GM-CSF act as autocrine growth factors for tumour cells. These cytokines could be prometastatic or pro-angiogenic and their deregulated expression directly correlates with the metastatic potential of several human carcinomas. 17 Moreover, altered levels of pro-inflammatory and pro-angiogenic factors are observed in various forms of cancer. 18 Natural compounds contains a range of complex organic chemicals that may have synergistic effect on various physiological processes in normal and disease states by interacting with multiple metabolic pathways. 19 Many naturally occurring compounds have been reported as inhibitors of tumour-specific angiogenesis. [20] [21] [22] Fruits and vegetables contain a number of constituents associated with cancer prevention, 23 such as antioxidant vitamins and numerous micronutrients, including the plant phenolics. 24 Flavonoids constitute the most important single group of dietary phenolics and include catechins, pro-anthocyanins, anthocyanins, flavones and flavonols and their glycosides. Catechins are a class of flavonoids with potent antioxidant and cancer chemopreventive properties. High levels of monomeric (+)-catechin are found in the skins and seeds of fruit such as apples and grapes. 25 Studies of the biological effects of (+)-catechin in cell culture and in vivo indicate that this compound can inhibit lipid peroxidation 26 and intestinal tumour formation. 27 Very few data exist on the ability of flavon-3-ols such as (+)-catechin to inhibit angiogenesis in vivo.
In the present study, we evaluated the anti-angiogenic effect of (+)-catechin and its role in the production of nitric oxide and TNF-α in LPS-stimulated macrophages using both in vitro and in vivo models.
MATERIALS AND METHODS

Animals
Male C57BL/6 mice (4-6-weeks-old) were purchased from the National Institute of Nutrition, Hyderabad, India. The animals were fed with normal mouse chow (Sai Feeds, India) and water ad libitum. All animal experiments were conducted according to the rules and regulations of Animal Ethics Committee, Government of India.
Cell lines
Human umbilical vein endothelial cells (HUVECs) were isolated from human umbilical cord vein by collagenase treatment as described by Jaffe et al. 28 The cells were grown in medium 199, supplemented with 20% fetal calf serum (FCS), 100 units/ml penicillin, 100 µg/ml streptomycin and 2 ng/ml VEGF and FGF at 37°C in a 5% CO 2 atmosphere. B16F-10 melanoma cells and L929 cells were purchased from the National Centre for Cell Science (Pune, India). The B16F-10 melanoma cells were maintained in culture using DMEM with 10% FCS and L929 cells in MEM with 10% goat serum and antibiotics.
ELISA kits
Highly specific, quantitative, 'sandwich' ELISA kits for mouse IL-1β, IL-6, TNF-α, GM-CSF and IL-2 were purchased from Pierce Biotechnology (Rockford, IL, USA) and the ELISA kits for VEGF and TIMP-1 were purchased from R&D Systems (Minneapolis, MN, USA).
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Drug administration (+)-Catechin was purchased from Sigma (St Louis, MO, USA). (+)-Catechin was suspended in 1% gum acacia and administered intraperitoneally (i.p.) at a dosage of 200 µmole/kg body weight/dose/animal.
Determination of the effect of (+)-catechin on tumourspecific capillary formation
Angiogenesis was induced in two groups of C57BL/6 mice (n = 8 each) by injecting B16F-10 melanoma cells (10 6 cells/animal) intradermally on the shaven ventral skin of each mouse. Group I animals were kept as control animals treated with vehicle (gum acacia, i.p.) only. Group II animals were treated with five consecutive doses of (+)-catechin (200 µmoles/kg body weight/ dose/animal) starting simultaneously with the tumour challenge. The animals were sacrificed on 9th day after the induction of angiogenesis. The skin from the ventral side was dissected out, washed with PBS and the number of tumour-directed capillaries were counted using a dissection microscope at x20 magnification. 29 Determination of the effect of (+)-catechin on the production of IL-1β, IL-6, TNF-α, GM-CSF, IL-2, VEGF and TIMP-1 during angiogenesis Angiogenesis was induced in two groups of C57BL/6 mice (8 mice/group) as in the previous experiment. 29 Group I animals were treated with vehicle (1% gum acacia, i.p.) and kept as untreated control animals. Group II animals were treated with five consecutive doses of (+)catechin (200 µmoles/kg body weight/dose/animal) starting simultaneously with the tumour challenge. Blood was collected from all groups of animals at two time intervals (24th hour and 9th day after the induction of angiogenesis), the serum was separated and used for the estimation of IL-1β, IL-6, TNF-α, GM-CSF, IL-2, VEGF and TIMP-1 using ELISA kits according to the manufacturer's instructions.
Determination of the effect of (+)-catechin on serum nitrite levels during angiogenesis
C57BL/6 mice (16 animals) were divided into two groups (n = 8). Group I animals were treated with vehicle (1% gum acacia, i.p.) and kept as untreated control animals. Group II animals were treated with five consecutive doses of (+)-catechin (200 µmoles/kg body weight/dose/animal) starting simultaneously with the tumour challenge. Blood was collected from all groups of animals at two time intervals (24th hour and 9th day after the induction of angiogenesis) and the nitrite level in the serum was determined by Griess reaction. 30 Briefly, a 100-µl sample was treated with Griess reagent (one part of 0.1% N-(1-naphthyl)-diamine dihydrochloride in distilled water and one part 1% sulphanilamide in 5% concentrated H 3 PO 4 ) and incubated for 10 min at room temperature. Absorbance was estimated at 540 nm. The amount of nitrite was calculated from a NaNO 2 standard curve.
Determination of the effect of (+)-catechin on the production of TNF-α during angiogenesis (in vivo) by the L929 cell bio-assay
TNF-α can cause direct cytotoxicity to the TNF-sensitive lung fibroblast cell line (L929). Bio-assay of TNF-α is designed on the basis of this cytotoxicity, which can be used for the identification of murine TNF-α activity in tissue culture supernatants. 31, 32 L929 cells were plated in a 96-well titre plate at a concentration of 5000 cells/well. After 9 days of angiogenesis induction, serum from control as well as (+)-catechin-treated animals was added to the wells (50 µl/well) containing the target L929 cells in triplicate. The plates were then incubated at 37°C in a 5% CO 2 atmosphere for 48 h. The cell density was assessed by MTT assay. 33 Before 4 h completion of incubation, 20 µl of MTT (5 mg/ml) was added to each well. Formazan produced by mitochondrial succinate dehydrogenase was dissolved in dimethyl sulphoxide and absorbance was measured at 570 nm using an ELISA plate reader. Cellular cytotoxicity was also assessed morphologically by fixing the cells from the above experiment after 48 h of incubation using 5% formalin and staining with crystal violet.
Determination of the effect of (+)-catechin on the microvessel outgrowth from the rat aortic ring (rat aortic ring assay)
The rat aortic ring assay was used as the in vitro angiogenesis study model. 29 Dorsal aorta from a freshly sacrificed Sprague-Dawley rat was removed under sterile conditions and rinsed in ice-cold PBS. It was then cut into ~1-mm long pieces using surgical blades. Each ring was placed in a collagen pre-coated 96-well plate. The rings were incubated for 24 h at 37°C in complete medium and then replaced with conditioned medium from B16F-10 melanoma cells followed by incubation with or without escalating concentrations of (+)-catechin (5-25 µg/ml). On day 6, the rings were analyzed by phase-contrast microscopy for microvessel outgrowth and photographed.
Quantification of gene-specific mRNA of VEGF in B16F-10 melanoma cells
Quantikine mRNA is a novel method, which can be used to quantitate gene-specific mRNA at low levels. Briefly, B16F-10 cells (10 6 cells) were incubated with (+)-catechin (25 µg/ml) for 4 h at 37°C in a 5% CO 2 atmosphere. Following incubation, the cells were washed with PBS and mRNA preparations were made according to the manufacturer's procedure. mRNAs were hybridized with gene-specific, biotin-labelled, detection probes and digoxigenin alkaline labelled detection probes in a microplate. The hybridization solution was transferred to a streptavidin-coated microplate and the mRNA probe hybrid was captured. Following washes to remove the unbound conjugate, a substrate solution was added. Finally, an amplifier solution was added and the developed colour measured spectrophotometrically at 490 nm. 34 
Determination of cytotoxic activity of (+)-catechin towards HUVECs in culture by MTT assay
HUVECs were seeded (5000 cells/well) in 96-well flatbottomed titre plates and incubated for 24 h at 37°C in a 5% CO 2 atmosphere. Escalating concentrations of (+)catechin (5-25 µg/ml) were added and incubated for a further 48 h. Before 4 h completion of incubation, 20 µl MTT (5 mg/ml) was added. 33 The percentage of dead cells was determined using an ELISA plate reader set to record absorbance at 570 nm.
Determination of the effect of (+)-catechin on endothelial cell proliferation ([ 3 H]-thymidine incorporation assay)
HUVECs (5000 cells/well) were plated in a 96-well culture plate and incubated at 37°C in a 5% CO 2 atmosphere. After 24 h, various concentrations of (+)-catechin (5-25 µg/ml) were added along with 2 ng/ml VEGF and further incubated for 48 h. [ 3 H]-Thymidine was added to each well (1 µCi/well) and incubation was continued for an additional 18 h. After completing incubation, the plates were centrifuged, the culture supernatant was removed, the cells were washed three times with PBS and then treated with ice-cold PCA for 15 min. The resulting precipitate was dissolved in 0.5 N NaOH, scintillation fluid was added, and the radioactivity was counted using a Rack Beta liquid scintillation counter.
Determination of the effect of (+)-catechin on endothelial cell migration/motility
HUVECs were seeded into wells of collagen-coated 96-well plates at a density of 2 x 10 5 cells/well and incubated for 24 h at 37°C in a 5% CO 2 atmosphere. A clear area was scraped in the monolayer with a narrow tip by applying suction and washed with serum-free medium. Escalating concentrations of (+)-catechin (5-25 µg/ml) were added along with 2 ng/ml VEGF and further incubated for 24 h. After incubation, the cells were fixed in formalin, stained with crystal violet and photographed (x10 magnification). 35 
Determination of the effect of (+)-catechin on endothelial cell invasion
The invasion assay was carried out in modified Boyden chambers as described previously. 36 The lower compartment of the chamber was filled with serum-free medium 199 and a polycarbonate filter membrane coated with 25 µg Type I collagen was placed above this. HUVECs (10 5 cells/150 µl medium 199) were then seeded onto the upper chamber in the presence and absence of (+)-catechin (5-25 µg/ml) along with 2 ng/ml VEGF and FGF and incubated at 37°C in a 5% CO 2 atmosphere for 10 h. After incubation, the filters were removed, fixed with methanol and stained with crystal violet. Cells migrating to the lower surface of the polycarbonate filters were counted under a microscope. The results were expressed as percentage inhibition of invasion.
Determination of the effect of (+)-catechin on endothelial cell tube formation
Tube formation was carried out according to the protocol of Gupta et al. 37 Matrigel was allowed to thaw on ice at 4°C. Aliquots (30 µl) of ice cold matrigel were pipetted into a 96-well flat-bottomed titre plate without introducing air bubbles and kept for 30 min at 37°C to allow gelling of matrigel. HUVECs in medium 199 were seeded into the layer of matrigel at a density of 1 x 10 3 cells/well along with 2 ng/ml VEGF and FGF. Escalating concentrations of (+)-catechin (5-25 µg/ml) were added to the wells which were incubated for 48 h at 37°C in a 5% CO 2 atmosphere. After incubation, the cells were fixed with Diff Quick stain solution. Tube formation was examined and photographed using an inverted microscope (x 20 magnification).
Determination of the effect of (+)-catechin on the production of NO and TNF-α by LPS-stimulated macrophages (in vitro)
Peritoneal macrophages were elicited in BALB/c mice by injecting sodium caseinate. On the 5th day, the (+)-Catechin inhibits angiogenesis and NO production in LPS-activated macrophages 163 macrophages were harvested, washed, and cultured in 96-well titre plate with or without LPS (5 µg/ml) in the presence and absence of escalating concentrations of (+)-catechin (5-25 µg/ml) in a humidified atmosphere of 5% CO 2 at 37°C. The plates were centrifuged after 24 h and the supernatant was assayed for NO and TNF-α levels. The NO level was determined by the Griess reaction 30 and the amount of nitrite was calculated from a NaNO 2 standard curve. The TNF-α level was estimated using an ELISA kit according to the manufacturer's instructions. The supernatant was subjected to TNF-α bioassay. 31, 32 TNF-α bioassay was carried out using L929 cells. The L929 cells were plated at a density of 5000 cells/well. The supernatant (100 µl) obtained from the LPS-stimulated macrophages grown in the presence and absence of (+)-catechin was added to the L929 cells and incubated for 48 h. The cells were evaluated morphologically and the cell density assessed by MTT assay. 33 
Peritoneal macrophages were elicited in BALB/c mice by injecting sodium caseinate. On the 5th day, the macrophages were harvested, washed, and cultured in 96-well titre plate with or without LPS (5 µg/ml) in the presence and absence of escalating concentrations of (+)-catechin (5-25 µg/ml) in a humidified atmosphere of 5% CO 2 at 37°C. The plates were centrifuged after 24 h and the supernatant was assayed for NO and TNF-α levels. The NO level was determined by Griess reaction 30 and the amount of nitrite was calculated from a NaNO 2 standard curve. The TNF-α level was estimated using an ELISA kit according to the manufacturer's instructions.
Determination of the effect of (+)-catechin on L929 cell bioassay by LPS-stimulated macrophages (in vitro)
Peritoneal macrophages were elicited in BALB/c mice by injecting sodium caseinate. On the 5th day the macrophages were harvested, washed, and cultured in 96-well titre plate with or without LPS (5 µg/ml) in the presence and absence of escalating concentrations of (+)-catechin (5--25 µg/ml) in a humidified atmosphere of 5% CO 2 at 37°C. The plates were centrifuged after 24 h and the supernatants (100 µl) were transferred to L929 cells (5000 cells/well). The plates were then incubated at 37°C in a 5% CO 2 atmosphere for 48 h. Cellular cytotoxicity was assessed morphologically after fixing the cells using 5% formalin followed by staining with crystal violet.
Statistical analysis
Results were expressed as mean ± SD. The statistical analysis was done using one-way ANOVA followed by Dunnett's test.
RESULTS
Effect of (+)-catechin on tumour-specific capillary formation
The number of tumour-directed capillaries was significantly (P < 0.001) reduced in the (+)-catechin-treated animals (36.09%) compared to the control animals. The group which received (+)-catechin had an average of 25.5 ± 2.0 capillaries whereas the control group had an average of 39.9 ± 1.5 capillaries.
Effect of (+)-catechin on pro-inflammatory cytokines of angiogenesis-induced animals
The level of pro-inflammatory cytokines such as IL-1β, IL-6, TNF-α and GM-CSF is presented in Table 1 . In control animals, the level of IL-1β in the serum was markedly enhanced 24 h after tumour challenge (29.6 ± 2.1 pg/ml) which was double when compared to normal (17.0 ± 3.5 pg/ml) and maintained the same level even after 9 days. Although administration of (+)-catechin (27.0 ± 4.0 pg/ml) did not affect this initial elevation in the serum level of this cytokine at 24 h, it effectively reduced the IL-1β level close to normal (22.6 ± 3.6 pg/ml) by day 9 after angiogenesis induction.
The IL-6 level was found to be elevated in the serum of untreated angiogenesis-induced control animals 24 h after tumour induction (35.0 ± 5.8 pg/ml) compared to a normal level of 33.0 ± 7.5 pg/ml. On day 9, the level of IL-6 in serum of control animals was drastically elevated to 320.0 ± 9.5 pg/ml. Administration of (+)-catechin was found to be very effective in checking the large increase in IL-6 levels (39.0 ± 6.2 pg/ml on day 1 and 42.0 ± 5.8 on day 9) after tumour inoculation.
There was a significant enhancement in the level of serum TNF-α (175.0 ± 7.2 pg/ml) in untreated control animals after 24 h of angiogenesis induction compared to normal (20.0 ± 3.0 pg/ml) and was much more elevated on day 9 of tumour challenge (630.0 ± 9.6 pg/ml). Even though initial enhancement was observed at 24 h after tumour inoculation (158.0 ± 7.6 pg/ml), administration of (+)-catechin significantly reduced the elevated serum TNF-α level to 173.0 ± 8.4 pg/ml after the 9th day of tumour challenge compared to control animals.
The serum GM-CSF level was highly elevated 24 h after tumour challenge in the untreated control animals (70.0 ± 5.6 pg/ml) compared to normal level (19.0 ± 2.8 pg/ml); by day 9, the level was 75.2 ± 4.8 pg/ml. (+)-Catechin administration reduced the initial elevation to 37.8 ± 6.4 pg/ml and, by day 9, the serum GM-CSF level (22.2 ± 3.4 pg/ml) was found to be closer to normal values.
VEGF levels showed an elevation in both untreated control (62.0 ± 9.2 pg/ml) as well as in (+)-catechin (60.8 ± 5.6 pg/ml) treated animals after 24 h of tumour inoculation from the normal value of 16.0 ± 8.8 pg/ml. This increase persisted in control animals (150 ± 14 pg/ml) on the 9th day whereas, in (+)-catechin treated animals, it was only 56.5 ± 5.1 pg/ml on the same day.
Effect of (+)-catechin on IL-2 and TIMP-1 levels of angiogenesis-induced animals
The lowered levels of IL-2 in the control animals (16.0 ± 2.2 pg/ml) 24 h after tumour inoculation compared to normal levels (24.0 ± 3.0 pg/ml) was normalized by the treatment with (+)-catechin (23.8 ± 5.2 pg/ml). By day 9, administration of (+)-catechin (37.5 ± 5.6 pg/ml) significantly enhanced the level of IL-2 compared to untreated control (20.0 ± 2.6 pg/ml; Table 2 ).
The tissue inhibitor of metalloproteinase level in the serum of normal mouse was 600 ± 30 pg/ml which was reduced by the induction of tumour cells to 350.0 ± 19 pg/ml in the untreated control animals. But administration of (+)-catechin (610 ± 25 pg/ml) significantly elevated the level of this MMP inhibitor. A serum sample from the 9th day after tumour injection also showed a similar TIMP-1 profile in angiogenesis-induced animals. In control animals, it was 360 ± 22 pg/ml and (+)-catechin (802.0 ± 63 pg/ml) treatment maintained the initial elevation thereby checking MMPs ( Table 2 ). Values are expressed as mean ± SD. Blood was collected from the angiogenesis-induced animals at the indicated time points after tumour challenge. Serum was separated and the cytokine level was estimated by ELISA. ***P < 0.001.
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Effect of (+)-catechin on serum nitrite levels during angiogenesis
The effect of (+)-catechin on serum nitrite level is shown in Table 3 . The serum nitrite level of control animals was highly elevated (39.6 ± 1.20 µmol) after the 9th day of tumour challenge whereas administration of (+)-catechin significantly reduced the elevated serum nitrite level to 25.2 ± 0.86 µmol, on the same day which was nearer to normal serum nitrite level (22.2 ± 0.56 µmol).
Effect of (+)-catechin on the production of TNF-α (in vivo) by the L929 cell bio-assay
The effect of (+)-catechin on the production of TNF-α (in vivo) by the bioassay is shown in Table 4 . Serum from control animals produced 100% cytotoxicity to the TNF-α sensitive cell line ( Fig. 1B and Table 4 ). Serum from (+)-catechin-treated animals after the 9th day of angiogenesis induction produced very less cytotoxicity to the L929 cells ( Fig. 1C ) and cell growth was of normal pattern (Fig. 1A) . Cytotoxicity of the L929 cells to TNF-α was greatly reduced by the (+)-catechin treatment, which indicates that (+)-catechin could inhibit the TNF-α level in the serum.
Effect of (+)-catechin on the microvessel outgrowth from the rat aortic ring (rat aortic ring assay)
Conditioned medium from B16F-10 melanoma cells induced microvessel outgrowth from rat aorta ring ( Fig.  2A ). Treatment with (+)-catechin ( Fig. 2D ) at 25 µg/ml markedly inhibited the microvessel outgrowth from rat aortic rings induced by the conditioned medium from B16F-10 melanoma cells. The level of nitrite and TNF-α in the conditioned medium was found to be decreased after (+)-catechin treatment. At a concentration of 25 µg/ml, the nitrite and TNF-α levels were found to be significantly reduced to 35.8 µg/ml and 13.23 pg/ml, respectively, compared to the untreated control (95.2 µg/ml for nitrite and 20.18 pg/ml for TNF-α).
Effect of (+)-catechin on VEGF mRNA expression
Administration of (+)-catechin at a concentration of 25 µg/ml significantly inhibited (57.16%, 10.56 ± 2.0 attomoles/ml) 
Effect of (+)-catechin on endothelial cell proliferation
The rate of proliferation was determined by [ 3 H]-thymidine incorporation into the DNA of HUVECs. Thymidine incorporation is proportional to the potential of the cells to synthesize DNA. Proliferation was expressed as radioactive counts per minute (cpm). HUVECs showed very high rate of proliferation (4866 ± 220 cpm) when stimulated with VEGF. Administration of (+)-catechin at a concentration of 25 µg/ml significantly inhibited (57.91%, 2048 ± 85 cpm) VEGFinduced proliferation of HUVECs. Considerable inhibition of proliferation was also observed when (+)catechin was administered at concentrations of 5 µg/ml (27.04%, 3550 ± 120 cpm) and 10 µg/ml (45.49%, 2652 ± 102 cpm; Table 5 ). The concentrations of (+)-catechin used were non-toxic as shown by MTT assay (data not shown).
Effect of (+)-catechin on endothelial cell migration/motility
The effect of (+)-catechin on the motility of HUVECs is shown in Figure 3 . HUVECs migrated into the clear area when stimulated with VEGF ( Fig. 3B ). (+)-Catechin significantly inhibited the VEGF-induced migration of endothelial cells in a dose-dependent manner and maximum inhibition of endothelial cell migration was Fig. 3E) and was similar to that of 0-h incubation (Fig. 3A) . This concentration was nontoxic as is evident from MTT assay and hence the inhibitory effect could not be attributed to cytotoxic activity.
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Effect of (+)-catechin on endothelial cell invasion assay
HUVECs showed a high invasive property through the collagen matrix when stimulated with VEGF and FGF (Fig. 4A ). Large numbers of cells were found on the lower surface of the polycarbonate, but administration of (+)-catechin produced significant inhibition in the invasion of the collagen matrix by HUVECs in a dosedependent manner. At a concentration of 25 µg/ml, (+)-catechin significantly inhibited the invasion of HUVECs by 78% (Fig. 4D) , whereas at 5 µg/ml and 10 µg/ml (+)-catechin significantly inhibited the invasion of HUVECs by 33% ( Fig. 4C ) and 56% (Fig. 4D) , respectively.
Effect of (+)-catechin on endothelial cell tube formation
Treatment of HUVECs with (+)-catechin inhibited tube formation (Fig. 5 ). Incubation of HUVECs on matrigel with VEGF resulted in the formation of elongated tubelike structures (Fig. 5A ). (+)-Catechin effectively reduced the width and length of endothelial tubes at 25 µg/ml (Fig. 5B ). At concentrations of 5 µg/ml and 10 µg/ml, no marked inhibition of endothelial tube formation was observed (data not shown).
Effect of (+)-catechin on the nitrite and TNF-α production by macrophages
Incubation of macrophages with the bacterial endotoxin, LPS produced a high concentration of nitrite (74.75 ± 6.33 µmoles) compared to untreated macrophages (17.18 ± 1.10 µmoles). Treatment with (+)-catechin significantly inhibited nitrite production (28.24 ± 1.02 µmoles at 5 µg/ml; 21.50 ± 1.88 µmoles at 10 µg/ml; 19.20 ± 1.12 µmoles at 
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C D E 25 µg/ml) in LPS-stimulated macrophages. The percentage inhibition was found to be 62.22%, 71.23% and 74.31% for 5 µg/ml, 10 µg/ml and 25 µg/ml, respectively. Similarly, TNF-α production by LPS-stimulated macrophages was also found to be significantly inhibited by (+)-catechin treatment. Incubation of macrophages with LPS produced a higher concentration of TNF-α (150.0 ± 23.8 pg/ml) compared to the untreated macrophages (24.2 ± 2.8 pg/ml). Treatment with (+)-catechin at a concentration of 25 µg/ml significantly inhibited TNF-α production (36.2 ± 6.8 pg/ml) compared to the LPS-stimulated macrophages. (+)-Catechin at 5 µg/ml and 10 µg/ml inhibited TNF-α production and the concentration was found to be 150.0 ± 23.8 pg/ml and 122.2 ± 18.6 pg/ml, respectively. The percentage inhibition was found to be 18.53%, 36.33% and 75.86% for 5 µg/ml, 10 µg/ml and 25 µg/ml, respectively. Supernatants from (+)-catechin-treated, LPS-stimulated macrophages produced significantly less cytotoxicity 
(+)-Catechin inhibits angiogenesis and NO production in LPS-activated macrophages 169
A B
to the L929 cells ( Fig. 6 ) and the cell growth was in the normal pattern (Fig. 6A) . The supernatant obtained from LPS-stimulated macrophages alone produced 100% cytotoxicity to L929 cells by TNF-α (Fig. 6B) . Cytotoxicity of the L929 cells by TNF-α was highly reduced by (+)-catechin treatment and maximum inhibition was found at 25 µg/ml (Fig. 6E ).
DISCUSSION
It is widely accepted that small tumours remain dormant in the absence of angiogenesis and that tumour growth can be suppressed by inhibiting angiogenesis. 38 Neovascularization increases the probability of metastasis in part by facilitating the shedding of tumour cells into the circulation. Since angiogenesis is essential for tumour growth, inhibition of angiogenesis has a good chance of preventing cancer from becoming malignant. 39, 40 In this study, we analyzed the anti-angiogenic activity of (+)-catechin using both in vitro and in vivo assays. The decreased number of tumour-directed capillaries in C57BL/6 mice injected with B16F-10 melanoma cells after the administration of (+)-catechin indicates its potential to inhibit selectively tumour-specific capillary sprouting without damaging the pre-existing vasculature. Since tumour vasculature assures the supply of necessary nutrients and CO 2 , inhibition of new vessel sprouting should lead to the arrest of tumour growth and spread. 41, 42 Angiogenesis and inflammation are co-dependent process. 43 Inflammation may promote angiogenesis in a number of ways. 43, 44 Epidemiological studies have revealed a strong association between chronic inflammatory condition and carcinogenesis in several human can- 45, 46 Inflammatory breast cancer, which is fast growing, invasive and angiogenic over express several genes involved in angiogenesis. 47, 48 Nitric oxide and several pro-angiogenic as well as pro-inflammatory cytokines such as IL-1β, IL-6, TNF-α and GM-CSF contribute in the process of neovascularization. 49 The role of NO in tumour biology is ambiguous. NO may induce vasodilation or, as second messenger of other growth factors, give rise to enhanced permeability in tumour vasculature. In such cases, the blood flow in the tumour will be increased, which would provide favourable conditions for the tumour. 50, 51 To use an antiangiogenesis approach successfully as an anticancer therapy, it is essential to identify the agents that can decrease pro-angiogenic factors such as NO and TNF-α. Since (+)-catechin has been reported to inhibit angiogenesis and tumour growth in various cell lines, 52, 53 we investigated its effect on tumour-specific angiogenesis by analyzing the production of NO and pro-inflammatory cytokines during angiogenesis. Tumour vessel count has been directly correlated with the survival of tumour cells 54 and the administration of (+)-catechin significantly inhibited tumour specific angiogenesis in C57BL/6 mice. Interactions of endothelial cells of the tumour vasculature, tumour infiltrating immune cells such as T lymphocytes and macrophages, and the tumour cells themselves regulate the growth of solid tumours. Most of these cellular components have shown to generate NO in vitro. 55 It has been found that NO donor potentiates and NOS inhibitor attenuates angiogenesis induced by PGE 1 and macrophage conditioned media. 56 Some natural products and synthetic curcuminoids have been shown to inhibit tumour-specific angiogenesis through the down-regulation of NO production. 20, 57 The results of our present study correlate well with these findings. The intradermal introduction of highly metastatic B16F-10 melanoma cells resulted in a drastic elevation of serum NO levels in untreated angiogenesis-induced animals, which may the reason for increased tumour-directed capillary formation. However, the administration of (+)-catechin significantly reduced the elevated serum NO level after tumour challenge, which, in turn, resulted in decreased tumourdirected capillary formation. The down-regulatory effect of (+)-catechin was illustrated by its significant reduction of LPS-induced NO production. Inflammatory stimuli such as LPS induce NO in the process of macrophage activation, which mediates tissue responses in different phases of inflammation in a sequential and concerted manner. 58 The enhanced NO level thus acts as a promoter of angiogenesis and (+)-catechin significantly reduced the over-production of NO during angiogenesis; hence, it can be considered an anti-angiogenic agent.
The major sources of TNF-α are macrophages and, to a lesser extent, T-lymphocytes, proliferating B cells and NK cells. 59 TNF-α was found to be involved in the upregulation of NO synthesis since anti-TNF-α antibody treatment reduced the LPS-induced NO release by a murine macrophage cell line 60 and it also enhanced oxidative metabolism in human mononuclear phagocytes. 61 This results in the release of reactive oxygen intermediates including superoxides and H 2 O 2 that may cause cytotoxicity. 62 TNF and its exerted regulatory effect on both iNOS and VEGF has been found to upregulate MMP-9 expression and, thereby, angiogenesis. 63, 64 The antitumour mechanism of thalidomide is found to be related to serum levels of TNF-α in myeloma and it destabilizes TNF-α mRNA, thereby preventing angiogenesis. 65 Administration of (+)-catechin significantly reduced the dramatically enhanced TNF-α level on induction with B16F-10 melanoma as well as LPS. Bioassay, using serum of angiogenesis-induced animals as well as culture supernatant from LPS-stimulated macrophages, clearly confirmed that (+)-catechin down-regulated TNF-α levels as TNF-α-sensitive L929 cells exhibit a normal growth pattern in the presence of(+)-catechin. Thus, the elevation of NO and TNF-α from normal levels is strictly pro-angiogenic and the compounds which could down-regulate these pro-angiogenic factors can act as anti-angiogenic agents.
IL-1β has been proposed as the primary driver of cell growth, proliferation, matrix degradation and angiogenesis in invasive melanoma. 66, 67 Active secretion of IL-1β by tumour cells promotes their invasiveness but the degree of invasiveness may depend upon the concentration of secreted IL-1β. IL-1β knockout mice showed a lower degree of microvessel formation compared to the corresponding wild-type when induced with B16 melanoma. 68 Increased invasiveness of IL-1β secreting cells was shown to be mediated by enhanced tumour angiogenesis and increased angiogenic factor production (vascular endothelial growth factor and macrophageinflammatory protein 2) through communication networks between the malignant cells and stromal cells. 69 In our experiment, (+)-catechin treatment was found to inhibit IL-1β production in angiogenesis-induced animals. Thus, amentoflavone-mediated inhibition of IL-1β may contribute to diminished tumour angiogenesis, probably because secretable IL-1β activates, by autocrine/paracrine mechanisms, an inflammatory cascade in the tumour's micro-environment; however, this proposal needs further investigation.
IL-6 plays an important role in thrombocytosis and in the storage of VEGF in thrombocytes. 70 VEGF is an endothelial cell-specific mitogen which plays a key role in neovascularization. 71, 72 IL-6 has been shown to upregulate VEGF-A load in the platelet aggregate on the tumour endothelium. 73 Serum IL-6 and VEGF levels were positively correlated in advanced cancers. 70 In our studies, (+)-catechin treatment inhibited the production (+)-Catechin inhibits angiogenesis and NO production in LPS-activated macrophages 171 of IL-6 accompanied with reduced levels of VEGF in the circulation. Since IL-6 has been shown to activate several signalling pathways, including the Janus-activated kinase/signal transducer and activator of transcription 3 (Jak-STAT 3), phosphoinositol-3-kinase (PI-3K) and mitogen activated protein kinase pathways, [74] [75] [76] (+)-catechin treatment might have interfered with IL-6-mediated signalling, thereby affecting the integrity of thrombocytes and angiogenesis.
GM-CSF is a pleiotropic cytokine produced by a number of different cell types including macrophages, T-cell granulocytes, fibroblasts, endothelial cells and various carcinoma cells. Even though GM-CSF did not modulate endothelial cell functions related to inflammation, 77 it induces endothelial cells to proliferate and migrate. Tumours expressing GM-CSF have been shown to have megakaryocyte potentiating activity due to IL-6 and cause thrombocytosis. 78 Since thrombocytes release VEGF into the circulation, thereby promoting angiogenesis, inhibition of GM-CSF, by amentoflavone treatment might open novel molecular properties that interfere with common angiogenic signalling pathways triggered on VEGF release by thrombocytes.
VEGF, a potent growth factor for blood vessel endothelial cells showing pleiotropic responses that facilitate migration and proliferation of endothelial cells, is stimulated by TNF-α, IL-1β, and IL-6. 79, 80 Interestingly, VEGF induces NO synthase activity in endothelial cells and increases the permeability of endothelial cells. Hence, VEGF has become a target for anti-angiogenic therapy. The observation that the presence of (+)-catechin decreased the VEGF mRNA level in B16F-10 melanoma cells correlates well with the decreased serum VEGF level in angiogenesis-induced animals after (+)-catechin administration. Moreover, the rat aortic ring assay also showed inhibition in the sprouting of new vessels from the pre-existing endothelial cells, strongly supporting the efficacy of (+)-catechin in suppressing neovascularization.
IL-2 is of clinical value in natural immunity by stimulating natural killer cell and cytotoxic T-lymphocyte production. 81 In the present investigation, we found that administration of (+)-catechin significantly increased IL-2 levels, which may contribute to the stimulation of the immune system against the tumour growth.
Tissue inhibitors of metalloproteinases (TIMP-1) are natural inhibitors of MMPs which negatively regulate MMPs during extracellular matrix turn-over. An imbalance between protease and inhibitor levels has been reported to accompany tumour angiogenesis. 82 During the activation phase of angiogenesis, increased expression of TIMPs inhibits tumour-associated angiogenesis. However, inhibition of MMP activity is required in the resolution phase of angiogenesis to stabilize newly formed blood vessels and allow basement membrane deposition. 83 Treatment with (+)-catechin significantly up-regulated the TIMP-1 level leading to the inhibition of angiogenesis.
CONCLUSIONS
Angiogenesis is a critical process which involves a concerted sequence of events including endothelial cell proliferation, motility and invasion of endothelial cells through the extracellular matrix towards the angiogenic stimuli and tube formation. In the present study, we have demonstrated that (+)-catechin could inhibit migration and tube formation of HUVECs. This inhibition might be due to reduced proliferation of endothelial cells. The concentrations of (+)-catechin used in the present studies did not interfere with cell viability of endothelial cells. (+)-Catechin could inhibit tumour-specific angiogenesis and could inhibit the production of nitric oxide and TNF-α in LPS-stimulated macrophages. Further studies are in progress in our laboratory to reveal the exact mechanism of action behind this.
